Phase 2 N=167 A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
Schizophrenia
Primary: Change From Baseline in the 16-Item Negative Symptoms Assessment (NSA-16) — -2.7; -3.6 units on a scale — p=0.732
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=468 Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (A7501013)(COMPLETED)(P05771)
Schizophrenia
Primary: Change From Baseline in Negative Symptoms of Schizophrenia Measured by the Negative Symptom Assessment (NSA) Scale Total Score — 60.4; 61.3; -9.7; -9.2 Units on a Scale…
Phase 2 N=92 Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms
Schizophrenia and Predominant Negative Symptoms
Primary: Change From Open-label Baseline in Modified Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Week 10 Open-label Phase, Last Observation Carried…
Phase 4 N=57 Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia
Schizophrenia
Primary: Change in Negative Symptoms — 32.7; 33.5; 31.2; 32.3 units on a scale
Phase 3 N=453 Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia
Schizophrenia
Primary: Negative Symptom Assessment-16 (NSA-16) Total Score - Change From Baseline to Week 26 — -12.14; -11.09 score on a scale — p=0.4825
Phase 3 N=55 Trial of D-Cycloserine in Schizophrenia
Schizophrenia
Primary: Scale for the Assessment of Negative Symptoms (SANS) — -.46; -.41 units on a scale/weeks
Phase 2 N=403 Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)
Schizophrenia
Primary: Change From Baseline to Week 26 in the Negative Symptom Assessment-16 (NSA-16) Total Score — 61.8; 61.0; -10.5; -8.8 score on a scale — p=0.0434
N/A N=79 Motivational Negative Symptoms in Schizophrenia: Intervention and Biomarkers
Schizophrenia · Schizoaffective Disorder
Primary: Strauss-Carpenter Level of Function Scale — 97.69; 94.56 score on a scale
Phase 4 N=29 Modafinil Effects on Cognition in Schizophrenia Patients
Schizophrenia
Primary: Cognitive Performance — 76.7; 75.5; 67.2; 77.1 percentage correct of all trials
N/A N=55 Improving Negative Symptoms of Psychosis In Real-world Environments
Schizophrenia
Primary: Clinical Assessment Interview for Negative Symptoms (CAINS) — .0667; -.0588 score on a scale
N/A N=53 Benefits of Physical Exercise in Schizophrenia
Schizophrenia
Primary: VO2max — 4.0; 0.2 ml.kg-1.min-1 — p=0.02
Phase 4 N=62 Antidepressant Controlled Trial for Negative Symptoms in Schizophrenia
Schizophrenia
Primary: PANSS Negative Symptom Score — 21.5; 23 units on a scale — p=0.36
Phase 2 N=16 Biomarkers in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: PANSS Total — 77.9; 80 units on a scale — p=0.02
Phase 2 N=256 A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia
Schizophrenia
Primary: Change From Baseline on the PANSS NSFS at Week 12 — -3.1; -3.3; -3.4; -2.5 scores on a scale — p=0.426
N/A N=47 Virtual Reality Training for Social Skills in Schizophrenia
Schizophrenia
Primary: Social Attention: Social Engagement Latency (SEL) — 21618 msec
Phase 2 N=27 Effects of Oxytocin Nasal Spray on Social Affiliation
Schizophrenia
Primary: Social Affiliation Measured by Social Affiliative Role Play — 4.026; 4.111; 4.079; 4.194 units on a scale — p=0.758
N/A N=39 Anti-Inflammatory Treatment of Schizophrenia
Schizophrenia
Primary: Change in Persistent Positive Symptoms — 13; 14; 14; 14 units on a scale
N/A N=69 Cognitive Training for Patients With Schizophrenia
Schizophrenia · Schizoaffective Disorder · Other Primary Psychotic Disorders
Primary: UCSD Performance-based Skills Assessment Total Score (Measures Functional Capacity) — 82.7; 84.4 units on a scale
Phase 2 N=12 Effects of Galantamine on Cognition
Schizophrenia
Primary: RVIP Target Hit and False Alarm (Number of Responses) — 23.4; 22.8; 19.7; 14.88 Number of responses — p=0.898
N/A N=66 Artemisinin to Reduce The Symptoms of Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Change in Positive and Negative Syndrome Scale (PANSS) Score From the Beginning to the End of the Double-blind Treatment Phase Weeks 2-12 — 64; 68.13; 61.42; 66.32 units…
Phase 2 N=64 Sulforaphane to Reduce Symptoms of Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Change in Positive and Negative Syndrome Scale (PANSS) Score From the Start to the End of the Double-blind Treatment Phase — 81.0; 81.5; 81.7; 79.7 score on a scale
Phase 3 N=513 Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia
Negative Symptoms of Schizophrenia
Primary: Change From Baseline to Week 12 in PANSS Marder Negative Symptoms Factor Score (NSFS) — 25.2; 25.3; 24.3; -1.2 score on a scale — p=0.043
Phase 3 N=323 An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia
Schizophrenia
Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 13 or Early Discontinuation — 83.5; 85.7; 6.9; -3.1 units on a scale…
Phase 2 N=88 Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: MATRICS Consensus Cognitive Battery (MCCB) — 30.92; 30.32; 33.43; 32.76 T score
Phase 3 N=104 D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Wisconsin Card Sorting Test (WCST) — 38.43; 35.79; 43.14; 39.57 percentage of correct responses
Phase 2 N=58 Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Schizophrenia
Primary: Scale for the Assessment of Negative Symptoms (SANS) Total Score — 33.23; 36.63; 36.63; 30.07 units on a scale
Phase 4 N=33 Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Percent Change in Accuracy on High-control (i.e., Difficult) Condition of Preparing to Overcome Prepotency Task — 8.6; 9.2 percent change in accuracy
N/A N=31 Cigarette Smoking in Smokers With and Without Schizophrenia
Tobacco Dependence · Schizophrenia
Primary: End-of-session Carbon Monoxide — 62.7; 43.0 parts per million (ppm)
Phase 3 N=187 Long-Term Efficacy and Safety of Asenapine Using Haloperidol as a Positive Control (41513)(COMPLETED)(P05785)
Schizophrenia
Primary: Loss of Effect Over Time — 7; 15; 6; 3 Participants
N/A N=105 Improving Negative Symptoms & Community Engagement in Veterans With Schizophrenia
Schizophrenia · Serious Mental Illness
Primary: Clinical Assessment Interview for Negative Symptoms Motivation & Pleasure Scale (CAINS MAP) - 12 Weeks — 19.8; 17.3; 17.4; 17.1 score on a scale — p=0.295